Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

Rhea-AI Summary

Impel Pharmaceuticals (NASDAQ: IMPL) announced that CEO Adrian Adams will present a company overview at the JMP Securities Life Sciences Conference on June 15, 2022, at 2:00 p.m. ET in New York. The event will focus on the company’s development of transformative therapies targeting high unmet medical needs, particularly in the central nervous system. A live webcast will be available on their Investors page, with a replay accessible for 90 days. Impel’s notable product is Trudhesa, a nasal spray for migraine treatment.

SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.

A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.

About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.

For additional information about Impel, please visit www.ImpelPharma.com 

Contact:

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com

Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com 

FAQ

What is the purpose of Impel Pharmaceuticals' presentation at the JMP Securities Life Sciences Conference?

Adrian Adams, CEO of Impel Pharmaceuticals, will present a company overview, focusing on their transformative therapies and unmet medical needs.

When is the JMP Securities Life Sciences Conference presentation scheduled for Impel Pharmaceuticals?

The presentation is on June 15, 2022, at 2:00 p.m. ET.

Where can I watch the live webcast of Impel Pharmaceuticals' conference presentation?

The live webcast will be available on the Investors section of the Impel Pharmaceuticals website.

What is Trudhesa, and how is it related to Impel Pharmaceuticals?

Trudhesa is a nasal spray developed by Impel Pharmaceuticals for the acute treatment of migraine in adults.

What type of therapies is Impel Pharmaceuticals focused on developing?

Impel Pharmaceuticals is developing therapies primarily targeting diseases of the central nervous system.